News | July 15, 2010

First Patient Enrolled in Vena Cava Filter Trial

July 15, 2010 – The first patient has enrolled in the Retrieve 2 U.S. trial, which will evaluate the safety and efficacy of Crux Biomedical's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter that is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.

The implant was performed by Jon Hupp, M.D., a vascular surgeon at Anne Arundel Medical Center, in Annapolis, Md.

“Current retrievable filters either require short term removal or seem to have an unacceptable frequency of migration or fracture issues,” Hupp explained. “Hopefully, the Crux filter will improve on this situation. There are a large number of patients who could benefit from such a device.”

Vena cava filters were originally designed as a permanent implant only. Subsequent design improvements have provided physicians with the option to retrieve the filter once a patient is no longer at risk of a PE. Presently in the United States, more than 50 percent of vena cava filters implanted are designed for retrieval at a later date. However, currently cleared vena cava filters are associated with a variety of complications. The Crux VCF design will prevent filter tilt and associated challenges in retrieval.

Related Content

Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init